Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Bladder Cancer treatment details. Biologic therapy. Chemotherapy. Dana-Farber Cancer Institute, Boston, MA, United States



Survival: 5.8 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: Boston, MA
   
Hospital: Dana-Farber Cancer Institute
   
Journal: Link
   
Date: 2/2012

Description:
Patients:
This study involved metastatic urothelial cancer patients who had been previously treated with a platinum-based therapy. Patients were divided into two separate treatment groups. Group A included 70 patients, 54.3% of whom were at least 65 years old and 68.6% were male. Group B had 72 patients, 45.8% of whom were at least 65 years old and 68.1% were male.

Treatment:
Patients in group A were treated with the chemotherapy agent docetaxel and the biologic therapy agent vandetanib, which is an inhibitor of proteins involved in supporting blood supply to tumors.
Patients in group B were treated with docetaxel only.

Toxicities:
There was one treatment-related death due to lung infection in group A. Grade 3-4 neutropenia (14% of patients), diarrhea (7%), and rash/photosensitivity (11%) were also reported.

The most severe adverse effects in group B were of grade 4 and included grade 3-4 neutropenia (14% of patients) and infection (6%).

Results:
The median overall survival rates for groups A and B were 5.85 and 7.03 months, respectively.

Support:
This study was partially supported by the pharmaceutical company AstraZeneca.

Correspondence: Dr. Toni K. Choueiri; email: Toni_Choueiri@dfci.harvard.edu

E-mail to a Friend Email Physician More Information